Rhododendrol-induced leukoderma is an acquired depigmentation that develops mainly at the contact site after repeated use of skin-whitening cosmetics containing rhododendrol. In most cases, cessation of further depigmentation or occurrence of repigmentation is observed after discontinuing the use of cosmetics. However, some patients develop vitiligo vulgaris through the spread of depigmentation into the non-exposed areas. Our study aims to investigate the patient-specific factors that may affect the extent of depigmentation or repigmentation, as well as development of vitiligo vulgaris. The degree of depigmentation of the face, neck and hands where exposed to rhododendrol was scored using photographs over time. The relationships between depigmentation score at first visit/improvement rate of depigmentation score and patient demographics were evaluated and three important clinical observations were made. First, repigmentation of the face was superior compared with that of the hands and neck, suggesting a possible role for the migration and differentiation of melanocyte stem cells from hair follicles, as a mechanism of repigmentation. Second, the intensity of rhododendrol exposure did not contribute to differences in the severity of depigmentation. This suggested a possibility of underlying genetic susceptibility to melanocyte cytotoxicity or immune reaction. Third, depigmentation score at first visit and past history of atopic dermatitis were significantly high in patients who developed vitiligo vulgaris. This suggested that severe chemical damage of melanocytes by rhododendrol leads to a higher risk of developing vitiligo vulgaris through the possible involvement of an immune reaction. These clinical observations may help to further understand the pathogenesis of rhododendrol-induced leukoderma.
INTRODUCTION
Chemical leukoderma is characterized by acquired depigmented skin lesions induced after repeated exposure to specific chemical substances. Phenolic derivatives have been known to induce chemical leukoderma. 1 Rhododendrol (4-[4-hydroxyphenyl]-2-butanol, Rhododenol â (Kanebo Cosmetics, Tokyo, Japan), abbreviated to RD) is a phenolic compound developed for producing hypopigmenting agents in Japan. 2 Cosmetics with RD content of 2% (w/w) have been available in the Japanese market since 2008. RD-induced leukoderma is an acquired depigmentation of varied severity, which develops after the repeated use of cosmetics containing RD mainly at the contact site. However, some patients also develop vitiligo vulgaris by the spread of depigmentation to non-exposed areas. RD-induced leukoderma has emerged as a social issue in Japan, and the cosmetics containing RD were recalled in July 2013. The manufacturer of RD has confirmed the development of depigmented lesions in 2% of the 800 000 users of their cosmetics.
In patients with RD-induced leukoderma, microphthalmiaassociated transcription factor-or Melan-A-positive melanocyte counts declined significantly compared with those in normal skin, but their complete disappearance as in vitiligo vulgaris was observed in only a few cases. 3 Loss of melanocytes is considered as a predictor of melanocyte cytotoxicity by RD. Further investigations have revealed the mechanism behind RD-induced leukoderma. RD is a competitive inhibitor of tyrosinase and thus reduces melanin production. The metabolized product of RD by tyrosinase has toxic effects on melanocytes through production of reactive oxygen species or ER stress. [4] [5] [6] [7] [8] Damaged melanocytes further trigger T-cell responses and activation of melanocyte-specific cytotoxic lymphocytes (CTL) which may enhance depigmented lesions leading to the spread of depigmentation to non-exposed areas. 9 As described above, the mechanism of RD-induced leukoderma has been revealed gradually, but some clinical questions need further investigation. In patients with chemical leukoderma, repigmentation may occur after discontinuing exposure to the chemical substances.
Similarly, in RD-induced leukoderma, cessation of further enlargement of depigmentation or occurrence of repigmentation after discontinuing the use of cosmetics is observed in most cases. 2 However, it is currently unknown if the tendency of repigmentation differs by different body parts. A few studies have shown that only a subset of patients with chemical leukoderma develop depigmented lesions even after a high-dose exposure to the chemical substances. 10, 11 Thus, it is possible that the chemicals are toxic only to individuals who are genetically susceptible. Furthermore, the manufacturer of RD has confirmed the occurrence of depigmented lesions in 2% of its 800 000 cosmetic users. 2 These results suggest that different susceptibilities to melanocyte damage or CTL responses may be present in patients with RD-induced leukoderma. 9 Nevertheless, whether patients heavily exposed to RD have a higher tendency to develop severe depigmented lesions is currently unknown as well. Exposure to phenolic compounds such as 4-tert-butylphenol and monobenzyl ether of hydroquinone is known to be a chemical trigger for initiating vitiligo vulgaris, which is also defined as contact/occupational vitiligo. 10, 12 Contact/occupational vitiligo is different from chemical leukoderma as it involves the spread of depigmentation beyond the site exposed to chemicals. Generation of reactive semi-quinone free radicals and induction of melanocyte cytotoxicity followed by an immune response are possible mechanisms responsible for the spread. Approximately 14% of RD-induced leukoderma patients developed vitiligo vulgaris according to the nationwide survey conducted by the Special Committee on the Safety of Cosmetics Containing RD. 13 Nonetheless, it is yet unknown if there are clinical aspects that are characteristic of the patients who developed vitiligo vulgaris.
To address these questions, we aimed to reveal patientspecific factors that may affect the extent of depigmentation or repigmentation as well as development of vitiligo vulgaris in RD-induced leukoderma patients through clinical observations.
METHODS Patients
A retrospective case study was conducted on RD-induced leukoderma patients who visited Sapporo Medical University Hospital between July 2013 and September 2014. Patients with a history of using cosmetics containing RD, followed by subsequent development of depigmentation lesions at the site of use, were included. The following parameters were recorded from the medical chart: sex, age, duration of RD exposure, types of cosmetics that the patient used (e.g. lotion, emulsion, cream, serum), time since cessation of exposure at first visit, inflammatory symptoms like pruritus or erythema accompanied by depigmented macule, treatments, exposed areas and affected areas. As a measure of the degree of exposure to RD, an RD exposure scale was calculated as: (duration of RD exposure [months] 9 number of different cosmetics that the patient used). Skin biopsies of depigmented lesions exposed to RD were conducted in 15 patients. Disappearance of melanocytes was evaluated by Melan-A staining. Family and past history of vitiligo vulgaris, and past history of thyroid disease, collagen disease, atopic dermatitis, asthma and pollen allergy, were also recorded.
Evaluation of depigmentation and repigmentation
Photographs of the face, neck and dorsal hands were taken from standard angles at the first and every subsequent visit. A physician visually assessed the photographs and determined the degree of depigmentation using the depigmentation score established by the Special Committee on the Safety of Cosmetics Containing RD. 2 The score was calculated on a scale of 0-8 for each of the six areas: (i) forehead; (ii) eyebrows/upper and lower eyelids/external canthi (abbreviated to "periorbital area"); (iii) cheeks; (iv) nose/area around the mouth (abbreviated to "nose and mouth"); (v) lower jaw/front of the neck/side of the neck (abbreviated to "neck"); and (vi) back of the hands/ between the fingers (abbreviated to "hands"). The degree of depigmentation was classified as 0 (no depigmentation), 1 (incomplete leukoderma) or 2 (complete leukoderma), and the extent of depigmentation was classified as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) or 4 (76-100%). Area score was obtained as: (degree of depigmentation 9 extent of depigmentation). The total depigmentation score is defined as the sum of the six area scores. The maximum possible value of the total depigmentation score is 48. Depigmentation scores at first (abbreviated to "first score") and last visits were evaluated. The first score was graded as mild and severe . The rate of improvement in the depigmentation score was calculated in patients followed up beyond 6 months. Patients whose score improved more than 75% were defined as the improved group. The relationships between the first score/improvement rate and the patient demographics were evaluated. Differences in the improvement rates of area scores between different body parts were also compared.
Patients were divided into two groups: (i) spread to nonexposed areas group; and (ii) limited to exposed area group. Differences in patient demographics, first score and improvement rate between the two groups were compared.
Statistical analysis and ethics
Statistical analysis was performed using Mann-Whitney U-test, v 2 -test and Fisher's exact test for appropriate comparisons between the two patient groups. Kruskal-Wallis test was used for ANOVA and Dunn's multiple comparison test was used for multiple comparisons. All tests were two-sided with 95% confidence interval. All statistical calculations were performed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA). This study was approved by the institutional review board of Sapporo Medical University (approval no. 272-1113).
RESULTS

Patient demographics
A total of 149 patients who developed depigmentation after the use of cosmetics containing RD were enrolled in the study. All patients, except one man, were women. Their ages ranged 23-85 years (median, 57). There were only three patients with a history of vitiligo vulgaris. Duration of RD exposure ranged 1-60 months (median, 24). RD exposure scale data was absent in six patients. Time since cessation of exposure at first visit ranged 0-31 months (median, 3). The number of patients with inflammatory symptoms was 64 (43%). Patients whose depigmented macules were limited to the exposed area were 137 (92%) whereas those whose macules spread to non-exposed areas were 12 (8%) in number. The face, neck and hands were exposed to RD in 98%, 77% and 55% cases, respectively. Other exposed areas (36%) were mainly the forearm and the posterior region of the neck. The face was the most common affected area (94%), followed by neck (65%) and dorsal hands (34%).
Severity of depigmentation at first visit Figure 1 shows histogram plots of patients' first scores. The median first score was 6 (range, 1-48), with 87% patients scoring mild and 13% scoring severe. Figure 2 shows area scores at the first visit. Because fewer people used the cosmetics on their hands, the number of patients who developed depigmented macules on their hands was lower than that of patients who developed depigmented macules on other areas. The patient demographics and severity at first visit are shown in Table 1 . Age, RD exposure scale, past history and inflammatory symptoms were not statistically different between the severe and mild groups. Disappearance of melanocytes was seen in six out of 15 patients, and was not different between the severe versus mild group (P = 0.235).
Repigmentation
Rate of improvement in the depigmentation score was analyzed in 104 patients who were followed up beyond 6 months. The median time since cessation of exposure at last visit was 18 months. The median duration of follow-up at last visit was 14 months (range, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The percentage of patients whose depigmentation score improved by more than 75% were 22 (21%) in number. None of the patients' depigmentation score was increased. The patient demographics and first scores as shown in Table 2 were not statistically different between the improved versus non-improved group. Disappearance of melanocytes was seen in five out of 13 patients who were followed up for more than 6 months, and it was not shown to affect improvement (P = 1.000).
Among the 104 patients, 46 received topical tacrolimus treatment for more than 3 months, and were defined as the topical tacrolimus group. The median duration of topical tacrolimus treatment was 10 months. There was only one patient per group who received topical vitamin D3 or phototherapy for more than 3 months. A total of 40 patients did not receive any treatment. The remaining patients received either various combinations of treatments or treatments for short durations. Effectiveness of topical tacrolimus therapy was evaluated; however, no difference in improvement was observed between the topical tacrolimus versus no treatment group (P = 0.167).
The rates of improvement at the nose and mouth (median, 75%), cheeks (median, 50%) and periorbital area (median, 70.8%) were significantly higher than those at the neck (median, 0%) and hands (median, 0%) (Fig. 3) . Furthermore, the rate of improvement at the forehead (median, 50%) was also significantly higher than that of the hands. These data reveal that significantly higher repigmentation was observed at the face compared with the hands and neck.
Development of vitiligo vulgaris
Past history of atopic dermatitis and first scores were significantly higher in the spread to non-exposed area group compared with patients in the limited to exposed area group (Table 3 ).
DISCUSSION
The current study has led to three important clinical observations. First, the repigmentation of the face is superior compared with that of the hands and neck. Second, the extent of RD exposure did not affect the severity of depigmentation. Third, the past history of atopic dermatitis and first scores were significantly high in patients who developed vitiligo vulgaris.
Repigmentation of the face is superior compared with that of the hands and neck. The third nationwide survey conducted by the Special Committee on the Safety of Cosmetics Containing RD showed that face lesions underwent remission in 81%, neck lesions in 74% and hands lesion in 64% of cases. 13 The third nationwide survey was a questionnaire performed with physicians between December 2014 and March 2015, and involved analysis of 981 cases. In this study, the degree of depigmentation was assessed as the depigmentation score using photographs and the rate of improvement in different body parts was compared statistically. In patients with chemical leukoderma, repigmentation is known to occur after cessation of exposure to the chemical substances, but the tendency of repigmentation by different body parts has not been investigated extensively. Acral lesions of vitiligo vulgaris are known to be resistant to therapy. 14 The low density of follicles that act as reservoirs of melanocytes is a commonly known theory. 15 Vellus hair follicle density in the face is higher than that in the arms. 16 Different from vitiligo vulgaris, melanocytes decline significantly in RD-induced leukoderma, but complete disappearance is observed only in a few cases. 3 Laboratory animal studies using brown and black guinea pigs exposed to RD have shown that epidermal melanocytes re-emerged spontaneously without any treatment after terminating exposure to RD, and thus repigmentation was observed. 17 The migration and differentiation of melanocyte stem cells from bulge or the secondary hair germ as well as migration of surrounding epidermal melanocytes are a possible mechanism of re- 2 (2) 2 (2) 0 (0) 1.000 Past history of thyroid disease, n (%) 11 (7) 9 (11) 2 (9) 1.000 Past history of collagen disease, n (%)
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3 (2) 1 (5) 2 (2) 0.353 Past history of atopic dermatitis, n (%) 11 (7) 2 ( emergence of epidermal melanocytes. In addition to repigmentation with residual epidermal melanocytes, melanocytes preserved in hair follicles may contribute to the better repigmentation in the face compared with the hands and neck in RD-induced leukoderma. The extent of RD exposure did not affect the severity of depigmentation. The manufacturer of RD has confirmed the occurrence of depigmented lesions in 2% of the 800 000 cosmetic users. 2 According to the investigation by the manufacturer of the cosmetics, the incidence rate of RD-induced leukoderma tends to be higher in individuals who use the lotion along with emulsion and cream containing RD compared with those who used lotion alone. 2 However, the correlation between extent of depigmentation and exposure of cosmetics has not been investigated extensively. On the other hand, a study has shown that only a subset of individuals develop depigmented lesions even after high-dose exposures to the chemical substances in chemical leukoderma or contact/occupational vitiligo. Thus, the chemicals may be toxic only to genetically susceptible individuals with a reduced ability of melanocytes to tolerate and/or respond to oxidative stress. 10, 11 Surprisingly, past history of vitiligo vulgaris had no influence on disease severity in contrast to our expectation that the inability of melanocytes to tolerate oxidative stress would ease the development of chemical leukoderma.
Patients who developed vitiligo vulgaris had higher first scores. Depigmentation scores evaluate depigmented macules of the face, neck and hands where they have been exposed to RD. There have been a few investigations on the immunemediated mechanisms of RD-induced leukoderma. The proportion of CCR4 + CD8
+ T cells in skin lesions as well as in blood was higher in RD-induced leukoderma patients than in controls. 18 According to Fujiyama et al., 19 among the human leukocyte antigen-A*02:01-positive patients, four out of six cases were positive for the Melan-A-specific CTL and there was a weak correlation between the percentage of body surface area undergoing depigmentation and the frequency of CTL. These findings suggest that CTL play an important role in RD-induced leukoderma, and the chemical damage of melanocytes may contribute to activation of melanocyte-specific CTL. Melanocyte-specific CTL may further induce the spread of depigmented macules to non-exposed areas. Our data suggests that severe chemical damage of melanocytes by RD can lead to a higher risk of developing vitiligo vulgaris. Moreover, patients who developed vitiligo vulgaris had a significant history of atopic dermatitis. Previous study has shown that the proportion of CCR4 + CD8 + T cells in both skin lesions and blood are higher in RD-induced leukoderma patients. 18 The concentrations of CCL17/thymus and activation-regulated chemokine (TARC) and CCL22/macrophagederived chemokine (MDC), ligands for CCR4, are higher in the blood, and CCL22 + monocytes were found to infiltrate into skin lesions of RD-induced leukoderma patients. Serum levels of CCL17/TARC and CCL22/MDC are known to be associated with the disease progression of atopic dermatitis and may play an important role in its pathogenesis. 20, 21 CCL17/TARC and CCL22/MDC may not only be involved in the pathogenesis of depigmented macules in RD exposed areas but also in spreading of depigmentation to non-exposed areas in RD-induced leukoderma.
Another noteworthy finding of the present study is that patients with severe or developed vitiligo tended to have a history of thyroid diseases, although this was not statistically significant. In patients with RD-induced leukoderma, the prevalence of antithyroglobulin antibody and antithyroperoxidase antibody was not found to be higher compared with the age-matched general population, according to the survey conducted by the Special Committee on the Safety of Cosmetics Containing RD. 22 On the other hand, vitiligo is well known to be often associated with thyroid disease especially in women, and some vitiligo susceptibility genes are shared among autoimmune thyroid diseases. [23] [24] [25] [26] The development of severe cases and/or vitiligo in RD-induced leukoderma may share this underlying genetic susceptibility to autoimmune thyroid diseases. Although outbreak of RD-induced leukoderma was by accident, many patients who suffered from a single chemical substance can give us clues to clarify the mechanisms of chemical A limitation of our study is that depigmentation scores cannot evaluate all depigmented lesions exposed to RD. Depigmentation scores can be used to assess depigmented lesions only on the face, neck and hands. Approximately 36% of patients had depigmented lesions in other areas like the forearm after exposure to RD.
In conclusion, our studies have shown that repigmentation of the face was superior compared with that of the hands and neck, suggesting the involvement of migration and differentiation of melanocyte stem cells from hair follicles as a mechanism of repigmentation. Further, the extent of RD exposure had no influence on the severity of depigmentation, suggesting a possibility of patient genetic susceptibility to melanocyte cytotoxicity or immune reactions. Patients who developed vitiligo vulgaris had significantly higher first score and past history of atopic dermatitis, suggesting that severe chemical damage of melanocytes by RD leads to a higher risk of development vitiligo vulgaris through a possible role of immune reactions by T-helper 2 chemokine. These clinical observations may advance the current knowledge on the pathogenesis of RDinduced leukoderma.
